BIBP 3226 trifluoroacetate
目录号 : GC11074
A nonpeptide antagonist of NPY receptor Y1
Cas No.:1068148-47-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BIBP 3226 trifluoroacetate is a non-peptide neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist with Ki values of 1.1, 79, 108 for rNPY Y1, hNPFF2, rNPFF, respectively.
Neuropeptide Y Y1 receptors (NPY Y1) involve in the regulation of exploratory behaviour and anxiety. Neuropeptide FF (NPFF) is a part of a neurotransmitter system functioning as a modulator of endogenous opioid functions [1].
BIBP 3226 was able to compete for the specific NPFF binding expressed in CHO cells as well as in rat dorsal spinal cord. In hNPFF2 receptors transfected cells, BIBP 3226 (10mM) is able to antagonize the inhibition of forskolin-stimulated cyclic AMP production induced by NPFF (10nM) in a concentration-dependent manner [2].
In male Wistar rats, BIBP3226 at the dose of 5 mg caused an anxiogenic-like effect while the lower dose was ineffective. While, the overall locomotory activity didn’t change in all treatment groups [1]. In mice model, BIBP3226 (5nmol) injected into the third ventricle completely antagonized the hypothermic effects of NPFF (30nmol) and NPVF (30nmol). In the mouse tail-flick assay, BIBP3226 (5nmol) prevented the anti-morphine actions of NPFF (10nmol). Also, in urethane-anaesthetized rats, BIBP3226 (500nmol/kg) significantly reduced the mean arterial blood pressure induced by NPFF (200nmol/kg) and NPVF (200nmol/kg) [3].
References:
[1]. Kask A1, R?go L, Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur J Pharmacol, 1996, 317(2-3): R3-4.
[2]. Mollereau C1, Gouardères C, Dumont Y, et al. Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol, 2001, 133(1): 1-4.
[3]. Fang Q1, Guo J, He F, et al. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides, 2006, 27(9): 2207-2213.
| Cas No. | 1068148-47-9 | SDF | |
| 化学名 | (R)-2-(2,2-diphenylacetamido)-5-guanidino-N-(4-hydroxybenzyl)pentanamide bis(2,2,2-trifluoroacetate) | ||
| Canonical SMILES | FC(F)(C(O)=O)F.OC1=CC=C(C=C1)CNC([C@@H](CCCNC(N)=N)NC(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C27H31N5O3.2CF3CO2H | 分子量 | 701.61 |
| 溶解度 | <7.02mg/ml in Water; <70.16mg/ml in DMSO | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4253 mL | 7.1265 mL | 14.2529 mL |
| 5 mM | 0.2851 mL | 1.4253 mL | 2.8506 mL |
| 10 mM | 0.1425 mL | 0.7126 mL | 1.4253 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。